CART-meso in Mesothelin Expressing Cancers

Inclusion Criteria: * Histologically confirmed cancer (one of the following): * Metastatic pancreatic adenocarcinoma. * Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinoma * Malignant pleural mesothelioma (histologically confirmed epithelial) * Failure of at least one prior standard of care chemotherapy for advanced stage disease. * Subjects must have measureable disease as defined by RECIST 1.1 criteria or modified RECIST criteria. * Patients \> 18 years of age. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy \> 3 months. * Satisfactory organ and bone marrow function as defined by the following (of note, the minimal blood counts should be in the absence of transfusion or cytokine support): i. Absolute neutrophil count \> 1,000/μl ii. Platelets \>75,000/μl iii. Hemoglobin \> 9 g/dL iv. Bilirubin \< 2.0x the institutional normal upper limit unless secondary to bile duct obstruction by tumor v. Creatinine \< 1.5x the institutional normal upper limit vi. Albumin ≥2 vii. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 5x the institutional normal upper limit viii. Cardiac ejection fraction of \>55% as measured by resting echocardiogram, with no significant pericardial effusion. * Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤ 1.5 and a PTT \< 1.2 time the upper limit of normal unless the patient is therapeutically anti-coagul…